ApoB indicates apolipoprotein B; CAD, coronary artery disease; CVD, cardiovascular disease; FH, familial hypercholesterolemia; LDL, low-density lipoprotein; LDL-R, low-density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9.
F amilial hypercholesterolemia (FH) is a common yet underdiagnosed autosomal dominant disorder that affects %1 in 220 individuals globally. 1 FH is characterized by lifelong elevation of low-density lipoprotein cholesterol (LDL-C) and if untreated leads to early-onset atherosclerosis and increased risk of cardiovascular events. Affected men and women who are untreated have a 30% to 50% risk of a fatal or nonfatal cardiac event by ages 50 and 60 years, respectively. 1 The most common causes of FH are pathogenic variants of the LDL receptor (LDL-R) gene, which are responsible for 85% to 90% of genetically confirmed FH. Pathogenic variants of the apolipoprotein (ApoB) gene, resulting in decreased binding of LDL to the LDL-R, or gain-of-function mutations in the gene for proprotein convertase subtilisin/kexin 9 (PCSK9), resulting in increased destruction of LDL-R, are responsible for 5% to 15% and 1% of cases of FH, respectively. 2 Autosomal recessive FH, caused by homozygous mutations in the LDL-R adaptor protein-1, is associated with a mild homozygous FH (HoFH) phenotype and is beyond the scope of this review. 3 With the exception of HoFH, FH is generally a silent disease. HoFH typically presents with pathognomonic physical findings in childhood, including xanthelasmas, tendon xanthomas, and corneal arcus. By contrast, in the Spanish Familial Hypercholesterolemia Cohort study, xanthomas and corneal arcus were present in <15% and 30% of patients with heterozygous FH (HeFH), respectively. 4 However, the prevalence of these findings increases with age in untreated individuals.
Elevated total cholesterol (240 mg/dL [6.2 mmol/L]) is found in up to 28.5 million (11.7%) of Americans over the age of 20 years. 5 Coronary artery disease (CAD) and myocardial infarction (MI) are also very common cardiovascular conditions, with more than 1 million Americans estimated to have had an MI in 2018. 6 Individuals with genetically confirmed FH account for only a small percentage of these cardiac events. In the US National Heart Lung and Blood Institute's Exome Sequencing Project, only 2% of cases of premature MI in men <50 years and women <60 years of age were found to have a genetic defect in the LDL-R. 7 However, as many as 20% of MIs in younger men (<45 years of age) have been attributed to FH. 8 Given the broad range of causes of hypercholesterolemia and early-onset CAD, it is not surprising that FH is not always in the differential diagnosis for healthcare professionals when confronted with a patient presenting with early CAD. This represents a missed opportunity for the screening of family members (cascade screening) and the early initiation of potentially lifesaving therapies.
It is crucial to consider the diagnosis of FH in children with LDL-C persistently >160 mg/dL (4.1 mmol/L), adults with LDL-C >190 mg/dL (4.9 mmol/L) (especially if there is a family history of early-onset CAD), and in all patients with early CAD. Given that FH is an autosomal dominant disorder, an individual who is heterozygous for FH has a 50% chance of passing the gene to his or her children. Homozygous individuals who have identical mutations in both alleles, compound heterozygotes who inherited different mutations in both alleles of the same gene, or double heterozygotes who have mutations in 2 different genes, will have offspring who are all obligate heterozygotes, assuming their partner does not have FH. 9 This review will focus on HeFH and aims to highlight the differences between FH, which is present from birth, and hyperlipidemia secondary to suboptimal diet and lifestyle or other causes of acquired hyperlipidemia that develop later in life. Diagnostic tools and potential treatments for individuals with FH will also be discussed.
Diagnosis
FH is significantly underdiagnosed and undertreated, particularly in children. 10 The burden of early diagnosis of FH rests on primary care providers, who have the unique potential to help improve the detection and management of FH. 11 Universal lipid screening in children between the ages of 9 to 11 years, as recommended by the National Heart, Lung, and Blood Institute, American Academy of Pediatrics, American Heart Association, National Lipid Association, and American College of Cardiology, has the potential to substantially improve case finding. 12 Earlier lipid screening at the age of 2 years is recommended if a child has a strong family history of early onset CAD (males, aged <55 years; females, aged <65 years) in a parent, grandparent, aunt, uncle, or sibling; a parent with a total cholesterol >240 mg/dL (6.2 mmol/L); or if the child has underlying cardiac risk factors, such as diabetes mellitus or obesity. Screening between the ages of 9 to 11 years enables the best discernment between those with and without FH and avoids confounding lipid changes secondary to LDL-C reduction, known to transiently occur during puberty. Survey data suggest that fewer than one third of practicing pediatricians have adopted these recommendations. 13 Other obstacles to early diagnosis include the limited public awareness of FH as a disease entity, its inherited nature, and the potential cardiovascular consequences if left untreated. Data from the FH Foundation's CASCADE (Cascade Screening for Awareness and Detection) FH registry demonstrated that the diagnosis of FH occurred at a mean age of 50 years, by which time more than one third of the patients with FH had already experienced an atherosclerotic cardiovascular disease (ASCVD) event. 14 This underscores the need for much earlier universal screening, diagnosis, and treatment of FH.
FH is clinically diagnosed on the basis of a weighted combination of physical findings, personal or family history of hypercholesterolemia, early-onset ASCVD, and the concentration of circulating LDL-C. 15 Extensor tendon xanthomas (typically Achilles, subpatellar, and hand extensor tendons) with extremely elevated LDL-C levels are considered specific for FH. 16 Severe extensor tendon xanthomas have histological features that resemble foam cell formation and lipid accumulation in atherosclerotic plaques ( Figure 1 ). Hence, there is a modest correlation between the extent of tendon xanthomas and the extent of coronary atherosclerosis. 17 However, as previously noted in children and young adults, a family history of CAD and elevated LDL-C levels are often the only findings. The fasting LDL-C concentration is incorporated in all diagnostic criteria and has been the backbone of FH diagnosis; however, nonfasting lipid testing may be used for initial screening. Blood sampling for the diagnosis of FH should preferably be avoided during acute illnesses, or while taking medications known to increase LDL-C such as cyclosporine, amiodarone, hydrochlorothiazide, and chlorthalidone. 18 Chronic illnesses that elevate LDL-C, such as hypothyroidism and liver or renal impairment, should be ruled out. 19, 20 Although the diagnosis of FH can be made on the basis of clinical features, genetic testing may offer additional insight regarding cardiac risk and diagnosis. 1 Recent data from 7 case-control and 5 prospective cohort studies of >26 000 individuals suggest that at any given LDL-C level, having an identified FH mutation is associated with significantly higher cardiac risk than an individual with the same LDL-C but no apparent pathogenic FH mutation. 21 In this study, individuals with an LDL-C level ≥190 mg/dL (4.9 mmol/L) and no pathogenic FH mutation were at a 6-fold higher risk of CAD than the reference group with an LDL-C ≤130 mg/dL. However, individuals with an LDL-C level ≥190 mg/dL (4.9 mmol/L) and a pathogenic FH mutation were at a 22fold higher risk than the reference group, 21 possibly reflecting greater atherogenicity of lifelong LDL-C elevation in FH compared with LDL-C elevation acquired later in life.
Although there are no internationally agreed-upon criteria for the diagnosis of FH, useful diagnostic criteria have been developed. The main diagnostic tools used for FH include the US Make Early Diagnosis to Prevent Early Death (MEDPED) criteria (Table 1) , 22 the UK Simon Broome system (UK FH Register criteria; Table 2 ), 23 the Dutch Lipid Clinic Network criteria (Table 3) , 24 and the National Lipid Association expert panel recommendations (Table 4 ). 25, 26 The Dutch Lipid Clinic Network, which uses a scoring system to predict the likelihood of an index patient having FH, and the Simon Broome criteria are the only tools that incorporate genetic test results into their algorithm. In the Simon Broome criteria, a positive genetic test is sufficient for a definitive diagnosis of FH, while in the Dutch Lipid Clinic Network criteria, a positive genetic test should be accompanied by an additional measure (eg, elevated LDL-C levels) to fulfill the definite diagnosis criteria. Although the existing diagnostic tools differ from each other, both in structure and the cut-off values of the LDL-C level necessary for diagnosis, their predictive values are comparable. 25 Among these diagnostic strategies, the Dutch Lipid Clinic Network criteria provide the most detailed assessment of the likelihood of a diagnosis of HeFH and are sometimes favored by insurance providers for the purpose of denial or approval of treatment with PCSK9 inhibitors among patients with FH. More recently, the American Heart Association proposed a simple set of criteria; however, these criteria have not yet been widely accepted or implemented (Figure 2) . 27 Table 5 highlights some of the differences between these diagnostic criteria. The Familial Hypercholesterolemia Foundation, an organization dedicated to improving the awareness, diagnosis, and management of FH, has developed a mobile application 28 that can assist both patients and providers with diagnosing FH. A special flow chart to detect FH in children has been developed and tested by the European Atherosclerosis Society consensus panel. 29 
Genetic Testing
Diagnosis of FH may be confirmed with positive pathogenic genetic testing, 25 but cannot be excluded in the absence of a causative mutation. Genetic diagnosis of FH may involve testing for either known pathogenic variants in the genes for LDL-R, ApoB, and PCSK9 or whole-gene sequencing. 30 Depending on the setting, a substantial percentage of patients with a definitive clinical diagnosis of FH may not have an identifiable mutation, even with next-generation whole-gene sequencing. 18 In mutation-negative patients, hypercholesterolemia may be secondary to an unidentified mutation or may be polygenic in nature. However, polygenic hypercholesterolemia would not typically be associated with the autosomal dominant pattern of inheritance seen in many families with a clinical diagnosis of FH. LDL-C genetic risk scoring, using the weighted sum of the LDL-C-raising alleles involved in determining lipid concentrations, can be used as a potential tool to differentiate between patients with polygenic dyslipidemia (but not FH) and patients with FH who test negative using current genetic assays. 31 Additionally, 1 expert group has suggested the umbrella of FH to include 2 groups of polygenic individuals whose inheritance pattern suggests an autosomal dominant disorder. They have termed these groups polygenic FH and FH combined with hypertriglyceridemia. Both groups have high polygenic scores and multiple family members with dyslipidemia and CAD. The former group is noted to have LDL-C >190 mg/dL (4.9 mmol/L) while the latter may have LDL-C >190 mg/dL or a non-HDL-C >220 mg/dL (5.7 mmol/L) and triglycerides >300 mg/dL (7.8 mmol/L). 32 As noted previously, data from Khera and colleagues suggest that cardiovascular risk in these groups with polygenic dyslipidemia, while elevated compared with the general population, is not as high as those individuals with monogenic FH. 21 Consultation with a genetic counselor before genetic testing may be beneficial to ensure the patient understands the risks and benefits of genetic testing.
The results of genetic testing should complement clinical and nongenetic laboratory diagnoses. Effective cholesterollowering treatments, which may include statins, ezetimibe, PCSK9 inhibitors, and other agents, are indicated for the treatment of patients with presumed FH regardless of genetic test results.
Risk Prediction in FH
Current evidence suggests that mortality from ASCVD is higher in monogenic cases of FH compared with patients with polygenic hypercholesterolemia. In the Simon Broome Registry, the prevalence of a single pathogenic mutation in those with a definite diagnosis of FH were found to be significantly higher than those labeled as possible FH by the Simon Broome criteria (80% versus 25-30%). By comparing the mortality between these 2 groups, one can clearly show that FH patients with a single pathologic gene mutation are at increased risk of death compared with those with polygenic hypercholesterolemia. 33 Humphries et al studied the prevalence of ASCVD in FH patients enrolled in the Simon Broome Registry and assessed the odds of having ASCVD between those without monogenic mutation and those with 3 known pathogenic mutations (LDL-R, ApoB, or PCSK9 mutations). 34 Their results showed that the odds of having ASCVD is higher in monogenic FH. Indeed, each gene conferred different odds of having CAD in affected individuals (odds ratio of 1.8, 3.4, and 19.9, for LDL-R, ApoB, and PCSK9 mutations, respectively).
Another important aspect in stratifying the risk of atherosclerotic disease in patients with FH is the additive effect of other traditional risk factors of atherosclerosis in these patients. Many studies have found significant variations in the risk of ASCVD in FH patients based on their underlying cardiovascular risks. 35, 36 In a longitudinal study of 1900 adult patients with HeFH followed in the CASCADE FH Registry for a mean of 20AE11 months, the overall annualized ASCVD event rate was 2.21% (4.57% in patients with prior ASCVD; 0.82% in patients without prior ASCVD). Patient characteristics that were significantly associated with the incidence of ASCVD events were older age at diagnosis of FH, older age at enrollment in the longitudinal registry, male sex, lower HDL-C, and higher prevalence of hypertension and diabetes mellitus (P<0.001). There were trends for an association among incident ASCVD events and smoking, higher triglycerides, and higher body mass index (P<0.02). 37 The International Atherosclerosis Society released an expert consensus in 2016 suggesting risk stratification of LDL-C ≥160 mg/dL (4.1 mmol/L) Non-HDL-C ≥190 mg/dL (4.9 mmol/L) LDL-C ≥190 md/dL (4.9 mmol/L) Non-HDL ≥220 mg/dL (5.7 mmol/L) At the LDL-C levels listed below, the probability of FH is %80% in the setting of general population screening. These LDL-C levels should prompt the clinician to strongly consider a diagnosis of FH and obtain further family information:
LDL-C ≥250 mg/dL (6.5 mmol/L) in a patient aged ≥30 y LDL-C >220 mg/dL (5.7 mmol/L) for patients aged 20 to 29 y LDL-C ≥190 mg/dL (4.9 mmol/L) in patients aged <20 y FH indicates familial hypercholesterolemia; HDL, high-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; MEDPED, Make Early Diagnosis to Prevent Early Death; NLA, National Lipid Association; PCSK9, proprotein convertase subtilisin/kexin 9. *The NLA expert statement was not intended to be a substitute for the MEDPED, Dutch Lipid Clinic Network (DLCN), or Simon Broome criteria. In addition, the NLA recommends use of MEDPED, DLCN, and Simon Broome criteria for diagnosis of FH.
Heterozygous FH Homozygous FH Family History of FH
LDL-C ≥160 mg/dL (4.1 mmol/L) for children LDL-C ≥190 mg/dL (4.9 mmol/L) for adults + one first-degree relaƟve similarly affected or with premature CAD or posiƟve geneƟc tesƟng for an LDL-C-raising gene defect (LDL receptor, ApoB, or PCSK9)
Presence of both abnormal LDL-C-raising gene defect(s) and LDL-C-lowering gene variant(s) with LDL-C <160 mg/dL FH patients into severe and nonsevere FH categories based on their LDL-C level and presence of known clinical risk factors for ASCVD. 38 International Atherosclerosis Society defines these risk factors as age >40 years without treatment, male sex, smoking, lipoprotein(a) (Lp[a]) >50 mg/dL (75 nmol/L), history of early CAD in first-degree relatives, body mass index >30 kg/m 2 , and history of diabetes mellitus or chronic kidney disease. In untreated FH patients at their first presentation, International Atherosclerosis Society defines severe FH as either LDL-C >400 mg/dL (10.3 mmol/ L), or LDL-C >310 mg/dL (8.0 mmol/L) with 1 high-risk feature, or LDL-C >190 mg/dL (4.9 mmol/L) with 2 or more high-risk features. FH patients with clinical ASCVD or evidence of advanced subclinical ASCVD are also considered to have severe FH. Markers of subclinical ASCVD are defined as a coronary artery calcium score >100 Agatston units and/or >75th percentile, or computed tomography angiography with at least 1 obstructive lesion (>50%) or multivessel lesions (<50%).
Cascade Screening
Diagnosing FH in a child or parent provides the opportunity for cascade screening, which involves testing all first-degree relatives for elevated LDL-C or a known genetic mutation ( Figure 4 ). When first-degree relatives of the index patient are identified to have FH, they become the locus for further cascade screening of second-and third-degree relatives. 18, 39, 40 A number of studies in the primary care setting have successfully implemented strategies of either universal or opportunistic pediatric lipid screening, resulting in the diagnosis of FH in parents and siblings. 41, 42 The DECOPIN project also documented significant success in diagnosing FH among children whose parents were diagnosed both clinically and genetically as having definite FH. In fact, cascade screening of relatives has been given a Tier 1 classification by the US Centers for Disease Control and Prevention because of the efficacy with which FH can be diagnosed in this setting. 1
Lipoprotein(a)
Lp[a] consists of an LDL particle to which apolipoprotein(a) is covalently bound. The plasma concentration of Lp(a) is largely genetically determined and is associated with an increased risk of ASCVD when elevated. The results of earlier studies suggested that levels of Lp(a) may be elevated in patients with FH. Among patients with FH, the presence of elevated Lp(a) may be associated with a 2-fold increase in the risk of ASCVD above the already high risk of ASCVD attributable to FH alone. 43 Furthermore, a study including >1000 children with FH whose Lp(a) levels were >30 mg/dL (%45 nmol/L) demonstrated a 1.45-times higher incidence (95% CI 0.99-2.13; P=0.05) of having a parent with FH and premature cardiovascular disease (CVD). 44 Therefore, Lp(a) levels should be measured in the initial evaluation of patients with FH. 45, 44 Treatment Dietary and lifestyle modifications are the starting points for LDL-C lowering in patients with FH, but multidrug treatment is often required to achieve adequate LDL-C levels (Figure 4 ). In addition, all patients with FH should be counseled on the importance of not smoking or vaping, regular exercise, and maintaining a healthy body weight. ASCVD risk factors and comorbidities, such as hypertension and diabetes mellitus, should be treated.
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Pediatric Patients
There are currently no long-term studies in children with FH that establish a reduction in vascular events in association with early initiation of LDL-C-lowering treatment. Results from 1 study demonstrated that children with FH have significantly greater carotid intima-media thickness than their unaffected siblings, which may be detectable as early as 8 to 10 years of age. 46 During longitudinal follow-up, the difference in carotid intimamedia thickness between FH and non-FH siblings progressively increased. Results from another study demonstrated small amounts of coronary artery calcification (indicative of advanced plaque) in some adolescents with FH. 27 In addition, the results from another study showed that treatment with pravastatin for 2 years in children with FH aged 8 to 18 years resulted in stabilization or possible regression of carotid intima-media thickness. 47 On the basis of these findings, as well as the documented longterm safety of statins in children over 10 years of followup 48 and the Food and Drug Administration (FDA) approval of all 7 statins for the treatment of children with FH, treatment with statins (usually at reduced doses) is recommended beginning between the ages of 8 and 10 years in children with FH. Furthermore, the proven benefits of statins for ASCVD prevention and treatment of FH in adults support their use in this population. 49 Until recently there were no long-term studies in children with FH establishing a reduction in vascular events in association with early initiation of LDL-lowering therapy. We now have 20-year follow-up data on 214 children with genetically confirmed FH documenting that statin treatment during childhood slows the progression of carotid intimamedia thickness. Additionally, childhood statin therapy has now been shown to reduce cardiovascular events and cardiac death assessed through age 39. As compared with their FH affected parents (n = 156), who did not receive statins as children, the incidence of cardiovascular events and death from cardiovascular causes, was much lower in FH patients treated since childhood (1% versus 26% and 0% versus 7%, respectively). These new data affirm the importance of initiating statins in childhood in the setting of FH. 50
Therapies for Pediatric Patients with FH
A recently proposed LDL-C goal in pediatric patients is <110 mg/dL (2.8 mmol/L) 51 ; however, the specific goal in pediatric patients with FH has not yet been determined. LDL-C goals of either <100 mg/dL (2.6 mmol/L) or <130 mg/dL (3.4 mmol/L) have also been proposed. Several guidelines recommend the use of statins to lower LDL-C in children and adolescents who are 8 to 10 years of age or older and have an LDL-C level that is persistently ≥160 mg/dL (4.1 mmol/L) after 3 to 6 months of lifestyle modification, and a clinical presentation consistent with FH. 52 Pravastatin and pitavastatin are approved by the US FDA for children aged 8 years and above, 53 whereas the other 5 statins are FDA approved from the age of 10 years for children with FH. 54 The cornerstones of European management for HeFH include healthy lifestyle changes and statin treatment from 8 to 10 years of age. Further recommendations include a target LDL-C level of <130 mg/dL (3.4 mmol/ L) if >10 years of age, or ideally a 50% reduction from baseline if 8 to 10 years of age. 29 Ezetimibe is approved by the FDA for the treatment of patients with HeFH without age restrictions, but data have not been reviewed for children younger than 10 years of age or premenarchal girls. The 2018 American College of Cardiology/American Heart Association cholesterol guidelines found that the drug provides clinically meaningful LDL-C reduction without significant safety issues. 51 In a prospective, multicenter, placebo-controlled study including 248 children with FH aged 10 to 17 years, 33 weeks of ezetimibe in combination with simvastatin provided an additional 16% reduction in LDL-C compared with simvastatin alone. In addition, ezetimibe did not adversely affect growth and development, sexual development, or menstrual cycle length in girls. 55 Colesevelam, a bile acid sequestrant, is approved by the FDA for the treatment of boys and postmenarchal girls with HeFH aged 10 to 17 years as monotherapy or in combination with a statin. 56 It is modestly effective for lowering the LDL-C concentration by 13% to 18% and can be useful as adjunctive therapy in some children.
PCSK9 inhibitors, which lead to an increase in available LDL-R number and a reduction in LDL-C, have not yet been adequately studied or approved for use in children and adolescents with HeFH; however, clinical trials of alirocumab (NCT02890992) and evolocumab (NCT02392559 and NCT02624869) in this population are ongoing, with results expected soon.
Adult Patients
The 2018 American College of Cardiology/American Heart Association guidelines recommend lipid-lowering therapies for patients with a baseline LDL-C level of >190 mg/dL (4.9 mmol/L) or higher and include specific recommendations for patients with FH. 51 In patients 30 to 75 years of age with HeFH and an LDL-C level ≥100 mg/dL (≥2.6 mmol/L) on maximally tolerated statin and ezetimibe therapy, the addition of a PCSK9 inhibitor may be considered. Given that many patients with FH will have documented CAD and will continue to be at very high risk for future ASCVD, the guidelines suggest the use of an LDL-C threshold of 70 mg/dL (1.8 mmol/L) for the addition of nonstatins to statin therapy. 51 Nonstatins include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors. In addition, niacin may have utility for adjunctive LDL-C lowering in some patients with FH who are unable to achieve LDL-C goals despite multidrug treatment regimens. 57 Lipoprotein apheresis using the Dextran Sulfate Low-Density Lipoprotein Adsorption system (LA-15, Kaneka, Osaka, Japan), the only apheresis system available in the United States, may also be considered for select patients who meet the current FDA criteria of LDL-C >100 mg/dL (2.6 mmol/L) after maximally tolerable therapy in patients with FH and ASCVD.
Therapies for Adults with FH
Various organizations recommend treating patients with FH with high doses of high-intensity statins, which are capable of lowering LDL-C by 50% to 60% (Figure 3 ). 58 If high-dose, highintensity statins are not tolerated, the maximally tolerated statin dose should be prescribed. This can include moderateintensity statin therapy, which typically lowers LDL-C by 30% to <50%, or even low-intensity statins, which lower LDL-C by <30% (Figure 3 ). Early introduction of lipid-lowering treatment in patients with FH appears to reduce the development of coronary events. 59 In an observational cohort study of 1950 adults with FH followed for 8.5 years, a 76% reduction in cardiovascular events was reported in statin-treated patients versus untreated patients. 49 Unfortunately, many patients with FH are not identified and treated until later in life, sometimes not until after they have experienced an ASCVD event. 60 Ezetimibe targets NPC1L1 (Niemann-Pick C1-like protein 1), resulting in inhibition of cholesterol absorption from the intestine. The IMPROVE-IT (Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes) trial involved a blinded placebo-controlled treatment of 18 144 recent survivors of acute coronary syndrome with either simvastatin 40 mg daily or simvastatin 40 mg plus ezetimibe 10 mg daily for a median follow-up of 6 years. The primary end point was a composite of cardiovascular death, nonfatal MI, unstable angina requiring hospitalization, coronary revascularization, and nonfatal stroke. The LDL-C level was 69.5 mg/dL (1.8 mmol/L) in the simvastatin group and 53.7 mg/dL (1.4 mmol/L) in the simvastatin plus ezetimibe group. At study conclusion, the event rate was 34.7% in the simvastatin-treated group versus 32.7% in the simvastatin plus ezetimibe group, with an absolute risk reduction of 2.0%. The hazard ratio was 0.936 (CI 0.89-0.99; P=0.016) with a number needed to treat of 50 to prevent 1 event. 61 Bile acid sequestrants can be a useful adjunctive therapy for patients who require modest additional LDL-C lowering after treatment with statins and ezetimibe. Colesevelam is a polymeric water-absorbing hydrogel that works by binding bile acids in the intestine to form an insoluble complex that is then eliminated from the body in feces. 62 In a study conducted in adults with refractory FH, compared with placebo, the addition of colesevelam to a maximally tolerated regimen of a statin plus ezetimibe provided significantly greater reductions in LDL-C. Similarly, the results of another study demonstrated significantly greater reductions in LDL-C in pediatric patients with FH receiving colesevelam alone or in combination with statins. In both of these multinational studies, colesevelam was generally well tolerated, with gastrointestinal disorders being the most common treatment-related adverse event. 56 LDL-C reductions of 14% to 18% can be achieved with colesevelam, with potentially larger reductions of up to 25% to 30% achievable with higher doses of cholestyramine and colestipol. 63, 64 Alirocumab and evolocumab are fully human monoclonal antibodies targeted against PCSK9. These agents act to increase available LDL-R and markedly reduce plasma LDL-C levels as monotherapy and in combination with statins and ezetimibe. The efficacy and safety of alirocumab in patients with HeFH have been studied in 3 multicenter, randomized, double-blind, placebo-controlled, phase III clinical trials: ODYSSEY FH I, ODYSSEY FH II, 65 and ODYSSEY HIGH FH. 66 All 3 studies included patients who were taking maximally tolerated statin treatment with other lipid-lowering therapies and who were randomized to 78 weeks of treatment with the primary outcome of percent LDL-C reduction from baseline assessed at 24 weeks. 66, 67 In the ODYSSEY FH I (n=486) and ODYSSEY FH II (n=249) trials, patients were randomly assigned 2:1 to either alirocumab 75 mg subcutaneously every 2 weeks (Q2W) or matching placebo. If the LDL-C level remained >70 mg/dL (1.8 mmol/L) at 8 weeks, the dose of alirocumab was blindly increased to 150 mg at Week 12. The mean LDL-C level decreased from 144.7 mg/dL (3.7 mmol/L) at baseline to 71.3 mg/dL (1.8 mmol/L) (À57.9% versus placebo) at Week 24 in patients randomized to alirocumab in ODYSSEY FH I and from 134.6 mg/dL (3.5 mmol/L) to 67.7 mg/dL (1.8 mmol/ L) (À51.4% versus placebo) in ODYSSEY FH II (P<0.0001 for both studies). At Week 24, an LDL-C level <70 mg/dL (1.8 mmol/L) was achieved by 59.8% and 68.2% of patients in ODYSSEY FH I and FH II, respectively. LDL-C levels achieved at Week 24 were maintained throughout the 78-week study. Discontinuation because of adverse events was infrequent. In the ODYSSEY HIGH FH trial, 107 patients were randomly assigned 2:1 to either alirocumab 150 mg subcutaneously Q2W or matching placebo. Patients in this study had very high baseline LDL-C (196.3 mg/dL [5.1 mmol/L] in the alirocumab arm and 201.0 mg/dL [5.2 mmol/L] in the placebo arm). At Week 24, LDL-C decreased by 45.7% in the alirocumab arm and 6.6% in the placebo arm for a placebocontrolled difference of 39.1% (P<0.0001). As in the previous studies, LDL-C reduction was maintained throughout the 78week study, and 41% of patients achieved the prespecified LDL-C goals of <100 mg/dL (2.6 mmol/L) for high-risk patients and <70 mg/dL (1.8 mmol/L) for very high-risk patients. As in the previous studies, alirocumab was safe and well tolerated.
Patients successfully completing the aforementioned FH studies were invited to enroll in an open-label extension program (median total duration of treatment was 2.5 years, including 1.5 years of the parent trial), during which patients were treated with 75 mg of alirocumab Q2W. From Week 12 of the open-label extension, the dose of alirocumab could be adjusted as per physician's clinical judgment. LDL-C reductions achieved in the parent study were generally maintained throughout the open-label extension and alirocumab continued to be well tolerated. 68 The effect of evolocumab was evaluated in two 12-week trials of patients with HeFH: RUTHERFORD 69 and RUTHER-FORD 2. 70 In the RUTHERFORD trial, 167 patients were randomly assigned to evolocumab 350 mg, 420 mg, or placebo every 4 weeks (Q4W) for 12 weeks. Baseline LDL-C in this study was 156 mg/dL (4.0 mmol/L) while taking maximally tolerated lipid-lowering therapy (statins and ezetimibe). Patients assigned to the 350 mg dose lowered their LDL-C by 43%, whereas those assigned to the 420 mg dose lowered their LDL-C by 55% (P<0.001 for both doses). The placebo group experienced a 1% increase in LDL-C. 69 The RUTHERFORD 2 trial was a multicenter, randomized, double-blind, placebo-controlled intervention in 331 patients. Patients were assigned to receive 140 mg of evolocumab Q2W (n=111), 420 mg monthly (n=110), or placebo Q2W (n=55) or monthly (n=55) as a subcutaneous injection. At study conclusion, evolocumab 140 mg Q2W lowered LDL-C by 59.2%, and evolocumab 420 mg monthly lowered LDL-C by 61.3% compared with placebo (P<0.0001 for both doses). 70 As with the alirocumab studies, patients completing the RUTHERFORD studies were invited to participate in follow-up long-term, open-label, extension studies: OSLER I (52 weeks) and OSLER 2 (48 weeks). Although the duration of open-label treatment with evolocumab was shorter than the alirocumab studies, the long-term extension studies confirmed a persistent LDL-C reduction for up to 64 weeks. 71 The efficacy of alirocumab and evolocumab in the secondary prevention of cardiovascular outcomes has also been documented in the ODYSSEY OUTCOMES 72 and FOUR-IER trials, 73 respectively (total n=46 488). Although these trials did not specifically recruit patients with FH, it is likely that many patients with FH were included in these studies. The hazard ratio for the primary efficacy end point in each study was 0.85, with nearly identical CIs and highly statistically significant P values obtained in both studies (P<0.001). 72, 73 Alirocumab, but not evolocumab, was also shown to be associated with a significant reduction in allcause mortality. 74 Both agents were safe and well tolerated.
In some circumstances, adults with HeFH and very high LDL-C following maximally tolerated lipid-lowering therapy can be considered for lipid or lipoprotein apheresis (formerly known as LDL apheresis). The American Society for Apheresis recently released their 2019 recommendations for the use of apheresis. For the treatment of Lp(a) >50 mg/dL in CVD patients on maximum drug therapy, American Society for Apheresis has assigned a category II, grade 1B classification. 75 Category II is defined as a disorder for which apheresis is accepted as second-line therapy, either as a standalone treatment or in conjunction with other modes of treatment, and a grade 1B recommendation is considered a strong recommendation, with moderate quality evidence, that can apply to most patients in most circumstances without reservation. 75 Furthermore, data from observational clinical trials suggest that lipoprotein apheresis may reduce symptoms of angina by improving endothelial function and reduce cardiovascular events when performed regularly. 76 The results of other studies demonstrated an acute improvement in coronary microvascular dysfunction after lipoprotein apheresis in patients with FH. 77 A long-term 10-year study (mean 6 years) evaluated the efficacy and safety of cholesterollowering therapies in conjunction with lipoprotein apheresis in patients with FH with coronary heart disease. This study found that lipoprotein apheresis in combination with cholesterollowering therapy significantly reduced LDL-C levels compared with those who received cholesterol-lowering drug therapy alone. In addition, the rate of total coronary events over 10 years of follow-up was 72% lower in the apheresis group than in the drug therapy alone group (P=0.0088). 78 The ODYSSEY ESCAPE study was conducted in 62 patients with HeFH who underwent regular weekly or Q2W lipoprotein apheresis. Study participants were randomly assigned in a 2:1 ratio to receive blinded alirocumab 150 mg (n=41) or placebo (n=21) Q2W subcutaneously for 18 weeks. Alirocumabtreated individuals demonstrated a 75% reduction in the standardized rate of apheresis treatment compared with placebo-treated patients (P<0.0001). 79 Lipoprotein apheresis has also been shown to reduce Lp(a) levels and CVD events, and is used in some extreme cases specifically for Lp(a) lowering. 81 Likewise, the Efficacy and Safety of evolocumab Compared with Continued Lipoprotein Apheresis: Results of a Randomized, Controlled, Open-Label Study was conducted in 39 patients with pre-apheresis levels of LDL-C >100 mg/dL (2.6 mmol/L). Patients were randomly assigned to continue lipoprotein apheresis (n=20) at the same frequency or discontinue lipoprotein apheresis and begin subcutaneous evolocumab 140 mg (n=19) every 2 weeks for 6 weeks. At 6 weeks all participants received open-label evolocumab 140 mg every 2 weeks for 18 weeks. The primary end point was avoidance of lipoprotein apheresis at week 5 or 6, as a result of achieving an LDL-C <100 mg/dL (2.6 mmol/L) at week 4 regardless of randomization arm. Significantly more patients in the evolocumab versus the lipoprotein apheresis group met the primary end point of avoiding lipoprotein apheresis (84% versus 10%; treatment difference [95% CI], 74% [45, 87] ; P<0.0001), suggesting that certain patients may be treated with evolocumab in place of lipoprotein apheresis. 81 PCSK9 inhibitors provide an added benefit for statinintolerant patients, including patients with FH. The GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3) trial was a phase III, multicenter, randomized, double-blinded study that compared the effectiveness of evolocumab versus ezetimibe in hypercholesterolemic patients (n=511) who were unable to tolerate an effective statin dose. 82 Percentage change from baseline in LDL-C was assessed at Week 24 of treatment with either evolocumab 420 mg monthly or ezetimibe 10 mg daily. Results demonstrated significantly greater mean percentage reductions in LDL-C levels with evolocumab versus ezetimibe after 24 weeks of treatment (À52.8% versus À16.7% mg/dL, respectively; P<0.001). 83 Similarly, the ODYSSEY ALTERNATIVE trial compared alirocumab with ezetimibe in patients at moderate-to-high cardiovascular risk with statin intolerance (n=361). Compared with ezetimibe, alirocumab reduced mean LDL-C levels by 45.0% versus 14.6% (P<0.0001). 84 
Management of Lipids in Women with FH During Pregnancy
Total cholesterol and LDL-C increase in all pregnancies by 25% to 50%; however, because women with FH have higher baseline lipids, the absolute increase is more notable in FH pregnancies. 85 Compounding this is the recommendation that women discontinue statins, ezetimibe, and PCSK9 inhibitors from the time of attempting to become pregnant through until the completion of breast feeding. Bile acid sequestrants, which are not systemically absorbed, and lipid apheresis are approved during pregnancy. 86 Women with FH who have had well-controlled lipids before pregnancy should not be discouraged from becoming pregnant. Genetic counseling before pregnancy can help couples understand the risk of transmission of FH to their offspring. 1 While in general, statins are contraindicated during pregnancy, some experts have recommended their use after organogenesis beginning in the second trimester in the setting of known FH complicated by prevalent ASCVD and in HoFH. 87 These experts cited a large cohort study of 886 996 completed pregnancies, which included 1152 (0.13%) pregnancies where a statin was taken, after controlling for pre-existing conditions including diabetes mellitus. There was no increased risk of organspecific malformations found. 88 Other data suggest that statins may potentially have a role in the prevention of pre-eclampsia. 89 In fact, 1 group, in conjunction with the FDA, studied the role of pravastatin in 20 high-risk pregnancies. Beginning between Weeks 12 and 16 of gestation, women were randomized to pravastatin 10 mg or matching placebo. No women in the pravastatin group developed pre-eclampsia while 4 placebotreated women did. Importantly, there was no difference in side effects or congenital anomalies between the groups. 90 PCSK9 inhibitors, like other IgG antibodies, are known to cross the placental barrier. 91 It is interesting, however, that the package inserts of both alirocumab and evolocumab suggest that this may not occur during the first trimester. 92, 93 There are registries devoted to following the pregnancy outcomes of women who become pregnant while on the PCSK9 inhibitors.
More research is needed to determine the best approach to managing lipids in pregnant women with FH. In the absence of randomized clinical trials, all women with FH who become pregnant while on any lipid-lowering therapy should be closely followed in registries.
Experimental Lipid-Lowering Therapies in Development
Although options for lipid-lowering treatment have markedly increased since the first statin came on the market in 1987, there is still a need for new lipid-lowering agents with novel mechanisms of action. Several such agents are currently in clinical development.
Bempedoic acid is an oral small molecule that inhibits hepatic adenosine triphosphate citrate lyase, leading to inhibition of the production of acetyl coenzyme A, the final common substrate for both fatty acid synthesis and sterol synthesis upstream from 3-hydroxy-3-methylglutaryl-acetyl coenzyme A reductase, which is the target of statins. Bempedoic acid upregulates LDL-R and leads to LDL-C reduction. Data from a phase III 52-week clinical trial (n=2230) that included a small number (n=79) of individuals with FH demonstrated that, when added to maximally tolerated lipid-lowering therapy (statins [with the exception of simvastatin 40 mg or higher] and ezetimibe), bempedoic acid 180 mg once daily significantly lowered LDL-C by 18.1% (P<0.001), ApoB by 11.9% (P<0.001), and high-sensitivity Creactive protein by 21.5% (P<0.001), with good safety and tolerability. 94 Patients with FH seem to respond similarly to patients without FH. In addition, the ETC-1002 (Evaluation of Long-Term Efficacy of Bempedoic Acid) in CLEAR Wisdom (Patients with Hyperlipidemia at High Cardiovascular Risk) trial found that the addition of bempedoic acid to maximally tolerated statins in patients with hypercholesterolemia, including those with FH, significantly reduced LDL-C levels compared with placebo. 95 MGL-3196 (NCT03038022) is a thyroid hormone receptorbeta-selective agonist that has been studied in a phase II,12week, double-blinded, placebo-controlled trial in 116 patients with HeFH who, despite maximally tolerated statin therapy, had LDL-C levels >100 mg/dL (2.6 mmol/L). Study subjects initially received a daily dose of 100 mg of MGL-3196, but some subjects had their dose reduced to 60 mg/d based on pharmacokinetic data obtained at Week 2. LDL-C was reduced by18.8% versus placebo (P<0.0001). Levels of triglycerides, ApoB, Lp(a), and apolipoprotein CIII were also decreased. MGL-3196 appeared to be well tolerated. Data from this study were presented as a poster at the European Society of Cardiology (ESC) and have not yet been published. 96 However, MGL-3196 has demonstrated encouraging antidyslipidemic effects in rodent models, reducing non-HDL-C and liver triglycerides. 97 Inhibitors of angiopoietin-like 3 are being evaluated in individuals with HeFH, HoFH, and hypertriglyceridemia. Angiopoietin-like 3 is a protein secreted by the liver that increases triglycerides, LDL-C, and HDL-C. Loss-of-function variants of the ANGPTL3 gene have been associated with a reduction in triglycerides, LDL-C, and HDL-C, in association with reduced risk of CAD. Evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, was first studied in a single-group, open-label, 4-week study in 9 patients with HoFH (NCT02265952). Study participants were taking multiple lipid-lowering therapies, including statins, ezetimibe, lomitapide, and PCSK9 inhibitors. Despite multidrug LDL-C-lowering treatment, baseline LDL-C was 376AE240 mg/ dL (9.7AE6.2 mmol/L). Evinacumab substantially decreased LDL-C by 49AE23% (range 25-90%) at Week 4. The absolute LDL-C reduction was 157AE90 mg/dL (4.1AE2.3 mmol/L) (range 71-323 mg/dL [1.8-8.4 mmol/L]). 98 On the basis of these results, larger trials in both HeFH (NCT03409744) and HoFH (NCT03175367) are under way, with results expected in 2019 and 2022, respectively.
Gemcabene, a lipid-modulating agent in phase II development, appears to increase the clearance of very lowdensity lipoprotein from plasma, and inhibits cholesterol and triglyceride production in the liver. This results in reduction of very low-density lipoprotein-C, LDL-C, Apo B, triglycerides, and high-sensitivity C-reactive protein. Although several phase II studies have been conducted, only 1 small (n=8), nonrandomized, open-label, 12-week study included subjects with HoFH and HeFH (NCT02722408). Participants in this study received 300 mg of gemcabene daily for 4 weeks, followed by 600 mg and 900 mg daily for 4 weeks each. As per the company website, 99 baseline LDL-C decreased 39% in patients with HeFH and 15% in patients with HoFH.
Small interfering RNA molecules have recently been used to target hepatic production of PCSK9. Inclisiran (ALN-PCS) is a long-acting, synthetic small interfering RNA that is directed against PCSK9 messenger RNA to reduce LDL-C levels. 100 In ORION 1, a phase II multicenter, double-blind, placebocontrolled, multiple-ascending-dose trial (NCT02597127), inclisiran was administered as a subcutaneous injection in patients at high risk for cardiovascular disease with elevated LDL-C levels (defined as LDL-C >70 mg/dL [1.8 mmol/L] in patients with ASCVD and >100 mg/dL [2.6 mmol/L] in patients without ASCVD). Patients were randomized to receive either a single dose of placebo or 200, 300, or 500 mg of inclisiran, or 2 doses (on Day 1 and Day 90) of placebo or 100, 200, or 300 mg of inclisiran. The primary end point was the percentage change of LDL-C from baseline at 180 days. All doses of inclisiran achieved statistically significant reductions in LDL-C versus placebo at Day 180. The 2dose 300 mg regimen achieved the greatest LDL-C reduction of 52.6% (P<0.001). 101 A number of inclisiran studies in HoFH and HeFH are either completed or ongoing.
Lastly, LIB003 is a recombinant fusion protein consisting of a PCSK9-binding domain and human serum albumin. 102 It is being developed for the reduction of LDL-C in patients with heterozygous and homozygous FH, CVD, or those at high risk of CVD who require additional LDL-C reduction. 102 By binding to PCSK9 in plasma, LDL-C is lowered by %70% at higher doses, in association with reductions in ApoB and 20% to 30% reductions in Lp(a). 102 
Ongoing and Future Research
There are still significant gaps in our understanding of optimal diagnostic tools and management methods for individuals with FH. The Familial Hypercholesterolemia Foundation established the ongoing CASCADE-FH registry to address gaps in knowledge and identify barriers to comprehensive FH screening, identification, and treatment among 40 clinical sites across the United States. Patients with FH are being followed longitudinally to track changes in LDL-C-lowering therapy, LDL-C goal achievement, patientreported outcomes, and clinical outcomes. 103 Data as of February 2017 demonstrated that <50% of patients were aware of available treatment options and the increased risk of heart disease. 104 Results from the CASCADE-FH registry, and similar registries in Europe and Asia, will help inform optimal screening, diagnosis, and treatment strategies in FH.
Conclusions
FH is a common autosomal dominant disorder that results in markedly elevated LDL-C levels from birth and causes early-onset CAD. Early diagnosis provides an opportunity to initiate potentially lifesaving and inexpensive generic pharmacotherapy in childhood. Although multiple guidelines recommend universal screening beginning in childhood, it is estimated that only 10% of the 1.3 million Americans living with FH are aware of their diagnosis. Consequently, FH is often diagnosed in adulthood following a cardiac event. FH is eminently treatable with currently available lipid-lowering therapies that include statins, ezetimibe, bile acid sequestrants, niacin, and PCSK9 inhibitors, as well as lipoprotein apheresis in more severe cases. However, early initiation of aggressive LDL-C-lowering treatment is required to achieve the greatest reduction in ASCVD morbidity and mortality. Additional promising experimental lipid-lowering agents are in clinical development and may be useful in this endeavor. In the meantime, the prevention of early-onset ASCVD events and mortality depends on greater awareness of FH among healthcare professionals and patients.
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